The drug abuse problem in general and the wide spread use of marijuana in particular has focused attention on the chemistry and pharmacology of cannabinoids. Although rapid advances have been made in the chemistry and pharmacology of this class of compounds, the mechanisms involved in producing the various central nervous effects (CNS) have not been established. The long term goal of the synthetic program is to develop delta-9-tetrahvdrocannabinol (THC) analogs which will prove to be useful tools in elucidating the mechanism of action of cannabinoids. The present emphasis will be directed toward: (a) developing cannabinoid analogs with a specific pharmacological profile as analgesics (b) examining the profile of the 'silent antagonist' (c) developing and designing CB2 selective ligands (d) studying the role of the C-I substituent in THCs in 'ligand-receptor' interactions and (e) delineating between peripheral and central effects of cannabinoids. All these goals represent a continuation of the current program which has generated several noteworthy leads.
The specific aims are (1) development of agonists with selective pharmacological profiles, (2) development of 'silent antagonists', (3) development of CB2 selective THCs, (4) examine the nature of C-I substituent interactions with the receptor, (5) study peripheral acting agonists and antagonists and (6) generate new biological leads.The knowledge gained from the synthesis and pharmacological study of these analogs could be vital in the study of Structure Activity Relationships(SAR), tolerance, dependence and in the development of therapeutically useful drugs, and will lead to a better understanding of the mechanism of action of cannabinoids and will help combat the problem of drug abuse.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA005488-19
Application #
7086916
Study Section
Molecular, Cellular and Developmental Neurosciences 2 (MDCN)
Program Officer
Hillery, Paul
Project Start
1988-06-01
Project End
2007-07-31
Budget Start
2006-08-01
Budget End
2007-07-31
Support Year
19
Fiscal Year
2006
Total Cost
$350,320
Indirect Cost
Name
Organix, Inc.
Department
Type
DUNS #
161843057
City
Woburn
State
MA
Country
United States
Zip Code
01801
Nguyen, Thuy; Li, Jun-Xu; Thomas, Brian F et al. (2017) Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor. Med Res Rev 37:441-474
Ghosh, Sudeshna; Wise, Laura E; Chen, Yugang et al. (2013) The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model. Life Sci 92:498-505
Wiley, Jenny L; Marusich, Julie A; Zhang, Yanan et al. (2012) Structural analogs of pyrazole and sulfonamide cannabinoids: effects on acute food intake in mice. Eur J Pharmacol 695:62-70
Bátkai, Sándor; Mukhopadhyay, Partha; Horváth, B?la et al. (2012) ?8-Tetrahydrocannabivarin prevents hepatic ischaemia/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB2 receptors. Br J Pharmacol 165:2450-61
Wiley, Jenny L; Selley, Dana E; Wang, Pinglang et al. (2012) 3-Substituted pyrazole analogs of the cannabinoid type 1 (CB?) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB?, non-CB? mechanism. J Pharmacol Exp Ther 340:433-44
Ramesh, Divya; Ross, Gracious R; Schlosburg, Joel E et al. (2011) Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice. J Pharmacol Exp Ther 339:173-85
Kinsey, Steven G; Mahadevan, Anu; Zhao, Bingjun et al. (2011) The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects. Neuropharmacology 60:244-51
Wiley, Jenny L; Breivogel, Christopher S; Mahadevan, Anu et al. (2011) Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist. Eur J Pharmacol 651:96-105
Kinsey, Steven G; Nomura, Daniel K; O'Neal, Scott T et al. (2011) Inhibition of monoacylglycerol lipase attenuates nonsteroidal anti-inflammatory drug-induced gastric hemorrhages in mice. J Pharmacol Exp Ther 338:795-802
Mao, Yingying; Zhang, Ming; Tuma, Ronald F et al. (2010) Deficiency of PAR4 attenuates cerebral ischemia/reperfusion injury in mice. J Cereb Blood Flow Metab 30:1044-52

Showing the most recent 10 out of 12 publications